Earnings Releases·Nov 4, 2026, 4:15 PM ET

Outset Medical — Third Quarter 2026 Earnings Summary

Net revenue rose 14% YoY to $33.6 million, driven by 15% growth in product revenue and 12% growth in service revenue, while gross margin expanded 130 basis points YoY to 40.7%.
Net loss narrowed to $14.7 million from $17.8 million YoY, supported by a 5% reduction in operating expenses to $25.9 million, despite a slight increase in non-GAAP net loss to $12.9 million.
Reiterated full-year 2026 revenue guidance of $125 million to $130 million and expects non-GAAP gross margin to land in the low-40% to mid-40% range.
Tablo adoption continues to expand with over 1,000 U.S. healthcare facilities, while the company maintains a strong liquidity position with $140.7 million in cash and equivalents at quarter-end.